Efficacy endpoints
disability
EVENTS
The endpoints assessed were: ARR; confirmed disability worsening (CDW) events (increase from baseline Expanded Disability Status Scale score sustained for ⩾ 3/6 months (3/6mCDW) mean number of gadolinium-enhancing (Gd+) T1 lesions per scan; number of new/enlarging T2 (neT2) lesions per year; serum neurofilament light chain (sNfL) concentration at ASCLEPIOS I/II baseline, 3-/12 months post-baseline, and every 6 months thereafter; and NEDA-3 status (no 6mCDW events, no confirmed relapses, and no MRI activity (new Gd+ T1 or neT2 lesions)) in the core and extension periods, in Year 1, beyond Year 1, and overall. For further details, see 